The PUL test is an outcomes instrument that was specifically designed to assess upper limb function in ambulant and non-ambulant patients with DMD. Since Capricor may be required to repay some or all of the amounts awarded by CIRM, the Company accounts for this award as a liability rather than income.In 2016, Capricor received $3.1 million under the terms of the CIRM Award. Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Capricor Therapeutics Inc. industry. In September 2017, the Company completed the second operational milestone tied to the last patient completing one year of follow-up, for which approximately $0.3 million was received by Capricor in November 2017. At the time of writing, stock’s 50-day Moving Average stood at $5.02, while the 200-day Moving Average is $2.76. Now with the previous closing price of 2.53 this indicates there is a potential upside of 156.9%.
Capricor is developing its exosome technologies as a next generation platform in a variety of diseases. To receive the RMAT designation, the company submitted data from the HOPE-Duchenne Trial.The Phase I portion of the ALLSTAR trial was a 14-patient, open-label, dose-escalation study that was conducted to evaluate the clinical safety of CAP-1002 in patients who had experienced a large heart attack and who had residual cardiac dysfunction. The first trial is known as “Regression of Fibrosis and Reversal of Diastolic Dysfunction in HFpEF Patients Treated with Allogeneic CDCs.” Dr. Eduardo Marbán is the named principal investigator under the study. The analyst consensus points to a rating of ‘Buy’. The second trial is known as “Pulmonary Arterial Hypertension treated with Cardiosphere-derived Allogeneic Stem Cells.” In both studies, Capricor will provide the necessary number of doses of cells and will receive a negotiated amount of monetary compensation which is estimated to be approximately $2.1 million over several years.Exosomes, a form of extracellular vesicles, are nano-scale, membrane-enclosed extracellular vesicles, or “bubbles” that are secreted by cells and contain bioactive molecules, including proteins, RNAs and microRNAs. The RMAT designation makes therapies eligible for the same actions to expedite the development and review of a marketing application that are available to drugs that receive breakthrough therapy designation – including increased meeting opportunities, early interactions to discuss any potential surrogate or intermediate endpoints and the potential to support accelerated approval. Additionally, in pre-clinical studies, it has been shown that intravenous administration of CDCs increases exercise capacity and diaphragmatic function in an animal model of DMD.While CSps and their respective CDCs may originate from either a deceased human donor (allogeneic source) or from heart tissue taken directly from recipient patients themselves (autologous source), the methods for manufacturing CDCs from either source are similar.Capricor’s proprietary methods are focused on producing therapeutic doses of CDCs to boost the regenerative capacity of the heart and skeletal muscle, with the goal of improving cardiac and skeletal muscle function. Nevertheless, stock’s Earnings Per Share (EPS) this year is 60.10%. Capricor Therapeutics was originally incorporated in Delaware in August 2005 under the name Nile Pharmaceuticals, Inc. and the company changed its name to Nile Therapeutics, Inc., or Nile, in January … In patients receiving CAP-1002, 25 million cells were infused into each of their three main coronary arteries for a total dose of 75 million cells. Capricor Therapeutics Inc.’s current insider ownership accounts for 9.21%, in contrast to 3.50% institutional ownership. The trial was powered to detect a reduction in scar size, relative to placebo, as measured by MRI at the 12-month follow-up. The 12-month results are anticipated to be available in the first half of 2020. Capricor Therapeutics is evaluating CAP-2003 in pre-clinical studies for the treatment of various indications. The day 50 moving average is 1.46 while the 200 day moving average is … Two of the 14 patients, who were in the lower two of the four dose cohorts, died from progressive heart failure approximately one and three months prior to study conclusion. Importantly, the change in median left ventricular ejection fraction from baseline to 12 months maintained its level of statistical significance that was shown at six months (p=0.02 at both time points) and, on an absolute basis, continued to improve from six to 12 months. 3 whereby the total loan balance and all accrued interest under the CIRM Loan Agreement has been forgiven by CIRM thereby terminating Capricor and the Company’s obligation to repay the loan balance.The company's Phase I/II HOPE-Duchenne trial of CAP-1002 in DMD-associated cardiomyopathy is being funded in part through a grant award from CIRM for approximately $3.4 million, which was entered into in June 2016.From inception through March 31, 2018, the company financed its operations primarily through private and public sales of its equity securities, NIH and DoD grants, a payment from Janssen, a CIRM loan and a CIRM grant award.